Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 1
Abstract
Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely associated with the impressive reduction of acute rejections within the first year, long-term graft and patient survival remain almost unchanged and unsatisfactory. Incomplete control of chronic allograft injury but particularly the adverse effects of long-term immunosuppression, such as graft toxicity, diabetes, cardiovascular events, infections, and tumours continue to challenge the long-term success. In general, immunosuppression is applied as one-size-fits-all strategy. This can result in over- and under-immunosuppression of patients with low and high allo-responsiveness, respectively. Trial- and -error strategies to minimize or even completely wean of immunosuppression have a high failure rate. Consequently, there is an unmet medical need to develop biomarkers allowing objective risk stratification of transplant patients. To achieve this goal, we engaged in an academic-industrial partnership. The central focus of the European-wide BIO-DrIM consortium (BIOmarker-Driven IMmmunosuppression) is the implementation of biomarker-guided strategies for personalizing immunosuppress- ion to improve the long-term outcome and to decrease the adverse effects and costs of chronic immunosuppression in solid organ transplant patients. The concept includes four innovative investigator-driven clinical trials designed by the consortium.
Authors and Affiliations
Hans-Dieter Volk, Bernhard Banas, Frederike Bemelman, Oriol Bestard4, Sophie Brouard5,Cristina Cuturi, Josep M Grinyó, Maria Hernandez-Fuentes, Martina Koch, Björn Nashan,Irene Rebollo-Mesa, Alberto Sanchez-Fueyo, Birgit Sawitzki, Ineke J M ten Berge, Ondrej Viklicky, Kathryn Wood K9 and Petra Reinke
Keywords
Related Articles
- EP ID EP679276
- DOI -
- Views 206
- Downloads 0
Genomics Vault: A framework for precision medicine data management
A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different...
Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium
Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely asso...
The role of open innovation in biomarker discovery
Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable...
Personalized medicine: consequences for drug research and therapy
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases....
Validation of novel multiplex technologies
Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the...